We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Portage Biotech Inc (PRTG) NPV

Sell:$4.87 Buy:$5.40 Change: $0.20 (3.71%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$4.87
Buy:$5.40
Change: $0.20 (3.71%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$4.87
Buy:$5.40
Change: $0.20 (3.71%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.

Contact details

Address:
Clarence Thomas Building, Road Town
P.O. Box 4649
TORTOLA
VG1110
Virgin Islands (British)
Telephone:
+1 (416) 9291806
Website:
https://portagebiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PRTG
ISIN:
VGG7185A1369
Market cap:
$5.44 million
Shares in issue:
1.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Virgin Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ian Walters
    Chairman of the Board, Chief Executive Officer
  • Allan Shaw
    Chief Financial Officer, Secretary
  • Robert Kramer
    Chief Scientific Officer
  • Steven Innaimo
    Vice President - Project Management and Operations
  • Justin Fairchild
    Vice President - Development
  • Brian Wiley
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.